Hexarelin Research Guide

Hexarelin Reconstitution & BAC Water Guide

Hexarelin / Examorelin concentration, research evidence, and mathematical BAC-water calculations.

Hexarelin, also known as examorelin, is a synthetic hexapeptide growth-hormone secretagogue and GHRP-6 analog. Human studies have investigated its ability to stimulate growth hormone secretion, but the published research does not establish a universal BAC-water reconstitution volume or a clinically established human treatment protocol.

Research Compound GHRP / GH Secretagogue Not FDA-Approved
Hexarelin peptide and growth hormone secretagogue receptor illustration Stylized scientific illustration showing Hexarelin peptide interacting with a growth hormone secretagogue receptor. The illustration is conceptual and not a molecular structure. HEXARELIN Synthetic GHRP / GH secretagogue GHS-R SIGNALING Conceptual research schematic
Conceptual illustration of Hexarelin as a growth-hormone secretagogue. Not an exact molecular or receptor structure.
Research Snapshot
Compound
Hexarelin
(Examorelin)
Class
Synthetic hexapeptide
Research Category
GH secretagogue / endocrine research
Regulatory Status
No FDA-approved Hexarelin product identified
Human Evidence
Human pharmacology studies exist
Vial Quantities
No authoritative standardized research vial size established
Last Reviewed
September 10, 2026
Concentration Mathematics

How Much BAC Water for Hexarelin?

There is no single scientifically established BAC-water volume that applies to every Hexarelin research preparation. The liquid volume determines the resulting concentration: adding more liquid produces a lower concentration, while adding less liquid produces a higher concentration.

Key answer: BAC-water volume should not be inferred from a clinical dose. If a specific product has manufacturer or laboratory documentation, that documentation takes precedence over generic mathematical examples.
Example Vial Quantity 1 mL 2 mL 2.5 mL 3 mL 5 mL
1 mg 1 mg/mL 0.5 mg/mL 0.4 mg/mL 0.33 mg/mL 0.2 mg/mL
5 mg 5 mg/mL 2.5 mg/mL 2 mg/mL 1.67 mg/mL 1 mg/mL
10 mg 10 mg/mL 5 mg/mL 4 mg/mL 3.33 mg/mL 2 mg/mL
Important: The 1 mg, 5 mg, and 10 mg rows are mathematical examples, not claims that these are standardized Hexarelin commercial vial quantities.

How Much BAC Water Should Be Added to Hexarelin?

The scientifically accurate answer is that there is no universal Hexarelin BAC-water volume established by the authoritative literature reviewed for this page. Reconstitution volume and research dose are separate concepts.

If a research vial contains a known amount of Hexarelin, the resulting concentration can be calculated from the vial quantity and the liquid volume. For example, a hypothetical 5 mg vial combined with 1 mL would mathematically represent 5 mg/mL, while the same 5 mg quantity in 5 mL would represent 1 mg/mL.

Do not interpret the table as a dosing protocol. Published human Hexarelin studies used specific experimental doses, routes, populations, and monitoring conditions. Those research parameters do not establish a universal home, clinical, or commercial reconstitution procedure.

How Much BAC Water for Hexarelin 5 mg?

For a hypothetical 5 mg quantity, the mathematical concentration is determined by dividing 5 mg by the volume in milliliters.

  • 5 mg ÷ 1 mL = 5 mg/mL
  • 5 mg ÷ 2 mL = 2.5 mg/mL
  • 5 mg ÷ 2.5 mL = 2 mg/mL
  • 5 mg ÷ 3 mL = 1.67 mg/mL
  • 5 mg ÷ 5 mL = 1 mg/mL

How Much BAC Water for Hexarelin 10 mg?

For a hypothetical 10 mg quantity, the same concentration equation applies:

  • 10 mg ÷ 1 mL = 10 mg/mL
  • 10 mg ÷ 2 mL = 5 mg/mL
  • 10 mg ÷ 2.5 mL = 4 mg/mL
  • 10 mg ÷ 3 mL = 3.33 mg/mL
  • 10 mg ÷ 5 mL = 2 mg/mL

How Does BAC-Water Volume Change Hexarelin Concentration?

Assuming the total amount of Hexarelin remains constant, increasing the liquid volume decreases concentration. Decreasing the liquid volume increases concentration.

What Is Hexarelin?

Hexarelin, also called examorelin, is a synthetic hexapeptide belonging to the growth-hormone-releasing peptide family. FDA's substance identity database lists examorelin and hexarelin as synonyms and identifies its chemical formula and substance identity, while noting that inclusion in the database does not imply regulatory approval.

Published human research has primarily examined Hexarelin as a potent growth-hormone secretagogue. Early pharmacology studies investigated intravenous, subcutaneous, intranasal, and oral administration and measured endocrine responses, particularly growth hormone.

Entity definition
Hexarelin / Examorelin is a synthetic GHRP-6 analog and growth-hormone secretagogue studied primarily for its effects on GH secretion and related endocrine signaling.
Simplified Hexarelin growth hormone signaling pathway Conceptual diagram showing Hexarelin signaling through growth hormone secretagogue receptors and downstream hypothalamic-pituitary growth hormone signaling. Simplified Hexarelin Research Signaling Model HEXARELIN Synthetic GHRP secretagogue GHS-R Growth hormone secretagogue receptor ENDOCRINE RESPONSE ↑ GH secretion Other endocrine responses observed in human research Experimental endocrine pharmacology Simplified research schematic — not a complete biochemical pathway
Simplified conceptual pathway showing Hexarelin's relationship to growth-hormone secretagogue receptor signaling. It is not a complete biochemical pathway or molecular structure.

How Hexarelin Works

Hexarelin belongs to the growth hormone secretagogue family. Research indicates that it can activate the growth hormone secretagogue receptor (GHS-R), a receptor associated with ghrelin and synthetic growth-hormone secretagogues.

Human pharmacology studies demonstrate that Hexarelin can stimulate GH release, with responses depending on dose, administration route, physiological state, and the integrity of the hypothalamic-pituitary system.

Importantly, Hexarelin's endocrine activity is not limited to GH. Published studies have reported effects involving prolactin, ACTH, and cortisol, which is one reason research findings should not be reduced to a simple "GH-only" mechanism.

GH

Growth Hormone

The primary endocrine endpoint investigated in many Hexarelin human studies.

R

GHS Receptor

Hexarelin is a synthetic growth-hormone secretagogue associated with GHS-R signaling.

E

Endocrine Effects

Published research has also examined prolactin, ACTH, cortisol and other endocrine responses.

What Is Hexarelin Being Studied For?

Hexarelin has primarily been studied as an experimental growth-hormone secretagogue and as a tool for investigating GH-axis physiology.

  • Growth-hormone secretion and GH-axis physiology
  • Growth-hormone responses in healthy volunteers
  • Growth-hormone responses in selected patients with GH deficiency
  • Interactions between GH secretagogues and GHRH
  • Effects of glucocorticoid exposure on GH responses
  • Prolactin, ACTH and cortisol responses
  • Growth-hormone secretagogue receptor pharmacology
  • Experimental cardiovascular and cellular research
Evidence distinction: These areas describe research questions and experimental endpoints. They should not be interpreted as FDA-approved indications or established therapeutic uses.

Human Clinical Research

Hexarelin has been administered to human volunteers in controlled research studies. The strongest human evidence concerns short-term endocrine responses, especially the stimulation of growth hormone.

In a double-blind, placebo-controlled dose-response study, 12 adult male volunteers received single intravenous Hexarelin doses of 0.5, 1, and 2 micrograms/kg. GH increased in a dose-dependent manner and peaked at approximately 30 minutes before returning toward baseline. :contentReference[oaicite:2]{index=2}

Another human study evaluated intravenous, subcutaneous, intranasal, and oral administration in healthy volunteers, demonstrating route-dependent GH responses. :contentReference[oaicite:3]{index=3}

Research in patients with growth-hormone deficiency also found that Hexarelin could stimulate GH secretion in selected patients, while responses were markedly reduced when hypothalamic-pituitary connections were disrupted. :contentReference[oaicite:4]{index=4}

Doses Studied in Published Research

Research-dose notice: The doses below are historical experimental parameters reported in published studies. They are NOT BacScience dosage recommendations, prescribing instructions, or instructions for personal use.
Study Population Dose Studied Route Frequency Duration Key Finding
Imbimbo et al., 1994
PMID 7957536		 12 healthy adult men 0.5, 1, 2 µg/kg IV bolus Single doses Acute Dose-dependent GH response
Bowers et al./Turin group research
PMID 8126144		 Healthy young volunteers IV 1–2 µg/kg;
SC 1.5–3 µg/kg;
intranasal 20 µg/kg		 IV, SC,
intranasal, oral		 Single experimental administrations Acute GH response varied by route and dose
Loche et al., 1995
PMID 7673411		 Children/adults with GH deficiency 2 µg/kg IV Single test dose Acute GH response depended on underlying pituitary anatomy
Maccario et al., 2002
PMID 11888836		 Healthy volunteers Repeated SC experimental administration SC 2 or 3 daily administrations 24-hour endocrine assessment Examined effects on GH and other endocrine hormones
Historical study parameters are provided for scientific context only. They must not be converted into personal dosing instructions.

Preclinical Research

Hexarelin has also been investigated in animal and cellular models. Preclinical work has explored growth-hormone secretion, feeding-related signaling, cardiovascular effects, receptor biology, and cellular responses.

For example, experimental studies in rats have investigated Hexarelin-related orexigenic effects and hypothalamic signaling, while cellular studies have examined signaling through GHS-R and receptor desensitization. :contentReference[oaicite:5]{index=5}

Cardiovascular research has also explored Hexarelin's interaction with GHS-R and CD36-related pathways. These findings remain experimental and should not be interpreted as evidence of an established cardiovascular treatment. :contentReference[oaicite:6]{index=6}

Human vs. preclinical evidence: Results observed in animal models or isolated cells cannot automatically be translated into human clinical benefits, safety, dosing, or efficacy.

Hexarelin Research Reconstitution & Concentration

For concentration mathematics, the basic relationship is:

Concentration Formula
Concentration = Total Vial Quantity ÷ Liquid Volume

The equation uses the total amount of compound in the vial and the final liquid volume. It does not determine whether a particular diluent is appropriate for a specific product, nor does it establish a clinical dose.

5 mg ÷ 1 mL Mathematical concentration = 5 mg/mL
5 mg ÷ 2.5 mL Mathematical concentration = 2 mg/mL
10 mg ÷ 5 mL Mathematical concentration = 2 mg/mL

These examples demonstrate the arithmetic only. They do not establish that 1 mL, 2.5 mL, or 5 mL is an appropriate preparation volume for a Hexarelin product.

BAC Water vs. Hexarelin Concentration

BAC water volume and compound quantity represent different variables. If the vial contains the same total quantity of Hexarelin, changing the liquid volume changes the concentration but does not change the total quantity of Hexarelin present.

↑

Less Liquid

Less liquid produces a mathematically higher concentration when total compound quantity remains constant.

=

Same Quantity

Changing liquid volume does not change the total mass of compound originally represented by the vial.

↓

More Liquid

More liquid produces a mathematically lower concentration when the compound quantity remains constant.

BAC water is not automatically interchangeable with every research compound. The actual product documentation, formulation, sterility requirements, compatibility information, and applicable laboratory procedures must be considered independently of concentration arithmetic.

Research Limitations & Safety

Hexarelin has substantial historical human pharmacology literature, but that does not mean it has an established FDA-approved therapeutic indication.

FDA's substance identity system lists Hexarelin under the preferred substance name Examorelin and lists Hexarelin as a synonym. FDA explicitly states that availability of a UNII does not imply regulatory review or approval.

No FDA-approved Hexarelin drug product was identified in the FDA sources reviewed for this page.

Published human research also demonstrates that Hexarelin can affect more than GH alone. Studies have reported changes in prolactin, ACTH, and cortisol, meaning that experimental endocrine effects should be considered when interpreting the literature. :contentReference[oaicite:7]{index=7}

Important distinction:
  • Mathematical concentration ≠ clinical dose
  • Research dose ≠ recommended dose
  • Historical human study ≠ FDA approval
  • Community protocol ≠ validated scientific protocol
  • Product vial labeling ≠ universal Hexarelin standard

Frequently Asked Questions About Hexarelin

How much BAC water should be used for Hexarelin?
No universal Hexarelin BAC-water volume was identified in the authoritative sources reviewed. A liquid volume can be selected mathematically to produce a desired concentration, but that calculation does not establish that the volume is appropriate for a specific product.
How much BAC water for a hypothetical 5 mg Hexarelin vial?
There is no universal recommended volume. Mathematically, 5 mg in 1 mL equals 5 mg/mL, 5 mg in 2 mL equals 2.5 mg/mL, and 5 mg in 5 mL equals 1 mg/mL. These are concentration examples, not preparation instructions.
How much BAC water for a hypothetical 10 mg Hexarelin vial?
Mathematically, 10 mg in 1 mL equals 10 mg/mL, 10 mg in 2 mL equals 5 mg/mL, and 10 mg in 5 mL equals 2 mg/mL. These examples do not establish an appropriate preparation volume.
What is the Hexarelin concentration formula?
Concentration equals total vial quantity divided by liquid volume. For example, 5 mg divided by 2.5 mL equals 2 mg/mL.
Does adding more BAC water lower Hexarelin concentration?
Yes. Assuming the total compound quantity remains constant, increasing liquid volume lowers the resulting mathematical concentration.
Is Hexarelin the same as Examorelin?
Yes. FDA's substance identity database lists EXAMORELIN as the preferred substance name and HEXARELIN as a synonym.
Is Hexarelin FDA approved?
No FDA-approved Hexarelin drug product was identified in the FDA sources reviewed for this page. FDA's substance identity database identifies Examorelin/Hexarelin but specifically states that a UNII listing does not imply regulatory review or approval.
Does Hexarelin increase growth hormone in human studies?
Yes. Multiple controlled human studies reported increases in circulating growth hormone after experimental Hexarelin administration, with responses varying according to dose, route, and participant characteristics.
Has Hexarelin only been studied for growth hormone?
No. Although GH is the dominant research endpoint, human studies have also examined prolactin, ACTH, cortisol, and other endocrine responses.
Can a published Hexarelin research dose be used to calculate BAC water?
Not directly. A research dose describes an amount administered under specific experimental conditions. Reconstitution concentration is a separate mathematical variable based on compound quantity and liquid volume.
Does BacScience recommend a human Hexarelin dose?
No. BacScience's educational research content does not prescribe or recommend human Hexarelin treatment or dosing.

Explore More Research Resources

BAC Water Calculator Calculate concentration from custom vial quantities and liquid volumes. Research Compound Library Developer: insert the live Research Compound Library URL. Peptide Research Library Developer: insert the live Peptide Research Library URL. BAC Water Resources Developer: insert the relevant BAC-water education hub. Testing & Transparency Developer: insert the live testing and transparency page. Related Compound Research Developer: insert a verified related peptide research page. Related GH Research Developer: insert a verified GH-secretagogue research page. Research Stack Library Developer: insert only a verified educational stack URL.

Scientific References

The following references provide the primary scientific basis for the human pharmacology and mechanism sections of this page.

  1. Imbimbo BP et al. (1994). "Growth hormone-releasing activity of hexarelin in humans. A dose-response study." European Journal of Clinical Pharmacology. PMID: 7957536.
  2. Hexarelin administration route study. "Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man." Journal of Clinical Endocrinology & Metabolism. PMID: 8126144.
  3. Loche S et al. (1995). "The effect of hexarelin on growth hormone secretion in patients with GH deficiency." Journal of Clinical Endocrinology & Metabolism. PMID: 7673411.
  4. Hexarelin and hypothalamic-pituitary function. "The growth hormone response to hexarelin in patients with different hypothalamic-pituitary abnormalities." Journal of Clinical Endocrinology & Metabolism. PMID: 9814463.
  5. Maccario M et al. (2002). "Impact of two or three daily subcutaneous injections of hexarelin ... on 24-h GH, prolactin, ACTH and cortisol secretion in humans." European Journal of Endocrinology. PMID: 11888836.
  6. Hexarelin endocrine effects. "Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome." PMID: 9253314.
  7. Arvat E et al. (2001). "Endocrine activities of ghrelin ... comparison and interactions with hexarelin ... and GH-releasing hormone." Journal of Clinical Endocrinology & Metabolism. PMID: 11238504.
  8. FDA Substance Registration System. Examorelin / Hexarelin substance identity record. FDA UNII: 09QF37C617.
  9. Safety and efficacy of growth hormone secretagogues. Peer-reviewed review of human growth-hormone-secretagogue research and limitations of clinical evidence.

Last Scientifically Reviewed

Review Date September 10, 2026
Content Type Scientific research & concentration guide
Scope Hexarelin / Examorelin

This page summarizes published research and mathematical concentration principles. It does not provide medical treatment advice, prescribe Hexarelin, establish a clinical dose, or establish a universal BAC-water preparation.